These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 29950709)

  • 1. Amy Abernethy.
    Nat Rev Drug Discov; 2018 Jun; 17(7):462-464. PubMed ID: 29950709
    [No Abstract]   [Full Text] [Related]  

  • 2. GlaxoSmithKline cancer drug threatens Herceptin market.
    Waltz E
    Nat Biotechnol; 2005 Dec; 23(12):1453-4. PubMed ID: 16333273
    [No Abstract]   [Full Text] [Related]  

  • 3. Pricing increases for cancer drugs sparks investigation.
    Venkatesan P
    Lancet Oncol; 2017 Jul; 18(7):e372. PubMed ID: 28552213
    [No Abstract]   [Full Text] [Related]  

  • 4. 'Financial toxicity' looms as cancer combinations proliferate.
    Morrison C
    Nat Biotechnol; 2015 Aug; 33(8):783-4. PubMed ID: 26252117
    [No Abstract]   [Full Text] [Related]  

  • 5. Placing bets on biotech.
    Weintraub K
    Cancer Discov; 2011 Nov; 1(6):462. PubMed ID: 22586641
    [No Abstract]   [Full Text] [Related]  

  • 6. US hospitals object to changes in Genentech drug distribution.
    Furlow B
    Lancet Oncol; 2014 Dec; 15(13):e591. PubMed ID: 25499290
    [No Abstract]   [Full Text] [Related]  

  • 7. Expensive cancer therapies: unintended effects.
    Delude CM
    J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
    [No Abstract]   [Full Text] [Related]  

  • 8. Will Medicare Price Negotiation Delay Cancer-Drug Launches?
    Vogel M; Kesselheim AS; Feldman WB; Rome BN
    N Engl J Med; 2023 Oct; 389(17):1546-1548. PubMed ID: 37819215
    [No Abstract]   [Full Text] [Related]  

  • 9. Biomedicine. Pharma firms push for sharing of cancer trial data.
    Bhattacharjee Y
    Science; 2012 Oct; 338(6103):29. PubMed ID: 23042862
    [No Abstract]   [Full Text] [Related]  

  • 10. Cancer drugs can be four times more costly in some wealthy countries than in others.
    Kmietowicz Z
    BMJ; 2015 Dec; 351():h6578. PubMed ID: 26637341
    [No Abstract]   [Full Text] [Related]  

  • 11. Drugs are scarce as mix of programs aims to ease access.
    Brower V
    J Natl Cancer Inst; 2009 Oct; 101(19):1304-6. PubMed ID: 19755680
    [No Abstract]   [Full Text] [Related]  

  • 12. Impact of Regulatory Incentive Programs on the Future of Pediatric Drug Development.
    Yen E; Davis JM; Milne CP
    Ther Innov Regul Sci; 2019 Sep; 53(5):609-614. PubMed ID: 30983385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncologic Drugs Advisory Committee and conflicts of interest.
    Burki TK
    Lancet Oncol; 2016 Mar; 17(3):e95. PubMed ID: 26877161
    [No Abstract]   [Full Text] [Related]  

  • 14. Novel schemes skirt NICE barrier.
    Elvidge S
    Nat Biotechnol; 2011 Aug; 29(8):677. PubMed ID: 21822231
    [No Abstract]   [Full Text] [Related]  

  • 15. Obtaining financial support for patients receiving off-label drugs.
    Clancey JK; Card IC
    Oncol Nurs Forum; 2000 Jun; 27(5):769-70. PubMed ID: 10868389
    [No Abstract]   [Full Text] [Related]  

  • 16. Patient Financial Assistance Programs: A Path to Affordability or a Barrier to Accessible Cancer Care?
    Zafar SY; Peppercorn JM
    J Clin Oncol; 2017 Jul; 35(19):2113-2116. PubMed ID: 28459612
    [No Abstract]   [Full Text] [Related]  

  • 17. On the biotech pharm, a race to harvest new cancer cures.
    Roush W
    Science; 1997 Nov; 278(5340):1039-40. PubMed ID: 9381202
    [No Abstract]   [Full Text] [Related]  

  • 18. Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs.
    Kantarjian H; Mathisen MS; Lipton JH
    JAMA Oncol; 2015 Sep; 1(6):729-30. PubMed ID: 26182331
    [No Abstract]   [Full Text] [Related]  

  • 19. Cancer drug prices and the free-market forces.
    Kantarjian H; Zwelling L
    Cancer; 2013 Nov; 119(22):3903-5. PubMed ID: 24037953
    [No Abstract]   [Full Text] [Related]  

  • 20. Market spiral pricing of cancer drugs.
    Light DW; Kantarjian H
    Cancer; 2013 Nov; 119(22):3900-2. PubMed ID: 24002792
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.